Abstract
Changes in glycosylation of the constant domain (Fc) of monoclonal antibodies (mAbs) enhance antibody-dependent cell-mediated cytotoxicity independently of downstream effects following receptor blockade by the antibody, thus extending their indication. We investigated the safety, pharmacokinetics, pharmacodynamics and antitumour activity of tomuzotuximab, an IgG1 glycoengineered mAb against the epidermal growth factor receptor with enhanced tumour cytotoxicity in a phase I dose-escalation study (NTC01222637). Forty-one patients with advanced solid tumours refractory to standard therapies received tomuzotuximab weekly (12-1370 mg) or two-weekly (990 mg) on a three-plus-three dose escalation design. A maximum tolerated dose was not reached. The most frequent treatment-related adverse events were infusion-related reactions in 31 (76%) patients (grade 3, 12%), mainly confined to the first dose, and skin toxicities (grade 1 or 2) in 30 (73%) patients. Hypomagnesaemia was observed in 9 out of 23 evaluable patients (39%). Similar to cetuximab, tomuzotuximab concentrations increased proportionally to dose from doses≥480 mg with a median terminal half life (t½) of 82 hours, range 55-113 hours. Antitumour activity included one complete r...Continue Reading
References
May 3, 2002·The Journal of Biological Chemistry·Robert L ShieldsLeonard G Presta
Aug 2, 2005·Cancer Treatment Reviews·Eva Kimby
Sep 2, 2006·Clinical Colorectal Cancer·Marwan G FakihJeffrey Lombardo
Oct 27, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antoinette R TanEric H Rubin
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paula M FracassoChristopher R Garrett
Mar 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jun KuraiEiji Shimizu
Mar 14, 2008·The New England Journal of Medicine·Christine H ChungThomas A E Platts-Mills
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Jan 24, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Frédéric BibeauFlorence Boissière-Michot
Apr 3, 2009·The New England Journal of Medicine·Eric Van CutsemPhilippe Rougier
Jul 23, 2009·Oncology·Xiao SuShenhong Wu
Apr 20, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemFortunato Ciardiello
Sep 9, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis G Paz-AresJosep Tabernero
Feb 4, 2012·Current Clinical Pharmacology·Xue SongZhongyun Zhao
Feb 7, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Javier RodríguezJesus García-Foncillas
Dec 5, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Christian A GerdesPablo Umaña
Mar 15, 2014·Oncology Reports·Yuki SeoYuko Kitagawa
Oct 16, 2014·Expert Opinion on Investigational Drugs·Robert Williams
Citations
Oct 28, 2019·Clinical Pharmacokinetics·Belén P SolansIñaki F Trocóniz
Jun 25, 2019·ESMO Open·Christoph C Zielinski
Aug 15, 2020·Frontiers in Oncology·Wen-Qi CaiHong-Wu Xin
Nov 7, 2018·Proceedings of the National Academy of Sciences of the United States of America·John P GiddensLai-Xi Wang
Nov 19, 2020·FASEB BioAdvances·Götz LaibleHarry M Meade
Jun 3, 2021·Cancers·Ying GongWilfred T V Germeraad
Jul 31, 2021·MAbs·Susanne WingertErich Rajkovic